Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Koen van de Wetering

Showing results (21-30 of 58) with videos related to

Pageof 6
Sort By:
Drug Metabolism and Disposition: the Biological Fate of Chemicals|December 15, 2011
Oral availability of cefadroxil depends on ABCC3 and ABCC4Dirk R de Waart, Koen van de Wetering, Cindy Kunne, et al.
Analytical and Bioanalytical Chemistry|November 18, 2022
A new enzymatic assay to quantify inorganic pyrophosphate in plasmaStefan Lundkvist, Fatemeh Niaziorimi, Flora Szeri, et al.
Cell Death & Disease|July 19, 2023
Loss of function mutation in Ank causes aberrant mineralization and acquisition of osteoblast-like-phenotype by the cells of the intervertebral discTakashi Ohnishi, Victoria Tran, Kimheak Sao, et al.
Molecular Cancer Therapeutics|September 4, 2008
Contribution of the drug transporter ABCG2 (breast cancer resistance protein) to resistance against anticancer nucleosidesCornelia de Wolf, Robert Jansen, Hiroaki Yamaguchi, et al.
Cancer Prevention Research (Philadelphia, Pa.)|July 7, 2012
Lack of ABCG2 shortens latency of BRCA1-deficient mammary tumors and this is not affected by genistein or resveratrolSerge A L Zander, Ariena Kersbergen, Wendy Sol, et al.
International Journal of Molecular Sciences|July 2, 2021
Mutagenic Analysis of the Putative ABCC6 Substrate-Binding Cavity Using a New Homology ModelFlora Szeri, Valentina Corradi, Fatemeh Niaziorimi, et al.
Molecular Cancer Therapeutics|December 10, 2009
Abcc2 (Mrp2), Abcc3 (Mrp3), and Abcg2 (Bcrp1) are the main determinants for rapid elimination of methotrexate and its toxic metabolite 7-hydroxymethotrexate in vivoMaria L H Vlaming, Anita van Esch, Zeliha Pala, et al.
Biorxiv : the Preprint Server for Biology|August 8, 2025
High-dose oral pyrophosphate inhibits connective tissue calcification in Abcc6 null mice but affects bone structureIbtesam Rajpar, Nicholas Yancy, Jacob Beiriger, et al.
JBMR Plus|February 3, 2026
High-dose oral pyrophosphate inhibits connective tissue calcification in Abcc6 null mice but may affect bone structureIbtesam Rajpar, Nicholas Yancy, Jacob Beiriger, et al.
The Journal of Investigative Dermatology|August 1, 2025
American Hair Research Society Mentorship Grant Program: Short-Term Training Opportunities with ExpertsChristopher S Potter, Victoria Ceh, Valerie D Callender, et al.
Pageof 6

Showing results (21-30 of 58) with videos related to

Sort By:
Pageof 6
Drug Metabolism and Disposition: the Biological Fate of Chemicals|December 15, 2011
Oral availability of cefadroxil depends on ABCC3 and ABCC4Dirk R de Waart, Koen van de Wetering, Cindy Kunne, et al.
Analytical and Bioanalytical Chemistry|November 18, 2022
A new enzymatic assay to quantify inorganic pyrophosphate in plasmaStefan Lundkvist, Fatemeh Niaziorimi, Flora Szeri, et al.
Cell Death & Disease|July 19, 2023
Loss of function mutation in Ank causes aberrant mineralization and acquisition of osteoblast-like-phenotype by the cells of the intervertebral discTakashi Ohnishi, Victoria Tran, Kimheak Sao, et al.
Molecular Cancer Therapeutics|September 4, 2008
Contribution of the drug transporter ABCG2 (breast cancer resistance protein) to resistance against anticancer nucleosidesCornelia de Wolf, Robert Jansen, Hiroaki Yamaguchi, et al.
Cancer Prevention Research (Philadelphia, Pa.)|July 7, 2012
Lack of ABCG2 shortens latency of BRCA1-deficient mammary tumors and this is not affected by genistein or resveratrolSerge A L Zander, Ariena Kersbergen, Wendy Sol, et al.
International Journal of Molecular Sciences|July 2, 2021
Mutagenic Analysis of the Putative ABCC6 Substrate-Binding Cavity Using a New Homology ModelFlora Szeri, Valentina Corradi, Fatemeh Niaziorimi, et al.
Molecular Cancer Therapeutics|December 10, 2009
Abcc2 (Mrp2), Abcc3 (Mrp3), and Abcg2 (Bcrp1) are the main determinants for rapid elimination of methotrexate and its toxic metabolite 7-hydroxymethotrexate in vivoMaria L H Vlaming, Anita van Esch, Zeliha Pala, et al.
Biorxiv : the Preprint Server for Biology|August 8, 2025
High-dose oral pyrophosphate inhibits connective tissue calcification in Abcc6 null mice but affects bone structureIbtesam Rajpar, Nicholas Yancy, Jacob Beiriger, et al.
JBMR Plus|February 3, 2026
High-dose oral pyrophosphate inhibits connective tissue calcification in Abcc6 null mice but may affect bone structureIbtesam Rajpar, Nicholas Yancy, Jacob Beiriger, et al.
The Journal of Investigative Dermatology|August 1, 2025
American Hair Research Society Mentorship Grant Program: Short-Term Training Opportunities with ExpertsChristopher S Potter, Victoria Ceh, Valerie D Callender, et al.
Pageof 6